Skip to content

Derm-Biome Pharmaceuticals’ topical therapy shows positive results in preclinical skin cancer trial: drug prevents the development of precancerous skin conditions and treats existing skin cancers with no observable side effects.

Derm-Biome Pharmaceuticals, Inc 2 mins read

VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) -- The rates of precancerous skin conditions and skin cancers are soaring in many parts of the world. Actinic keratosis (AK) is the most common form of precancer, with over 40 million Americans a year developing this condition. Treating AKs before the cells become cancerous and spread to other parts of the body is crucial. For those patients with multiple AKs, common treatment options are chemotherapy creams and photodynamic therapy. Although effective, these treatments come with significant side effects, such as redness, blistering, and peeling, with recovery times that can be lengthy and uncomfortable. The global actinic keratosis treatment market size is projected to reach as high as $10 billion USD by 2031, fuelled by increasing cases of AK and rising healthcare spending.

Derm-Biome Pharmaceuticals is a Vancouver-based biopharmaceutical company that has developed a topical anticancer treatment for patients with or at high risk of developing multiple AKs. In a recent UV-induced skin cancer trial, mice were exposed to UVB radiation over a period of 25 weeks. The prolonged exposure mimics chronic sun exposure over time and replicates the gradual progression from precancerous skin conditions to cutaneous squamous cell carcinoma (cSCC). Topical application of Derm-Biome’s compound prior to UVB exposure significantly reduced the number and size of precancer lesions, while treatment blocked the progression of squamous cell carcinoma tumors.

Frédéric Couture, Researcher and Head of Pharmaceutical Sciences at TransBIOtech: “My research group conducted this study using Derm-Biome’s compound. The compound exhibited a significant protective effect without toxicity or side effects. Moreover, existing tumor progression was blocked with drug treatment. We actually noticed an improvement to the look of skin treated with the compound.”

Dr. Poul Sorensen, University of British Columbia Professor and Distinguished Scientist at BC Cancer Research Centre, and Derm-Biome CSO: “The results of these studies are very promising. We tested our compound using a very aggressive UV-induced skin cancer model. We observed highly significant decreases in the number of tumors in treated mice and strong preventative effects when mice were pretreated with the compound. These findings suggest that our compound has great potential to be a highly effective and well-tolerated agent for both the treatment and prevention of squamous cell carcinoma.”

Derm-Biome CEO Gordon Eberwein: “Currently available topical treatments cause debilitating side effects that make them unattractive to patients. There is a real need for safer and more targeted topical therapies.”

Derm-Biome expects to start topical formulation development this summer, with IND-enabling studies slated to begin in Q4.

About Derm-Biome Pharmaceuticals, Inc.
Derm-Biome Pharmaceuticals, Inc. is a preclinical biopharmaceutical company dedicated to improving skin health. We are developing novel topical therapies for inflammatory skin diseases and precancer/non-melanoma skin cancers that are both highly effective and well tolerated by skin.

Derm-Biome is about to kick off a $3M USD seed funding round. For investor inquiries please contact:

Gordon Eberwein

A photo accompanying this announcement is available at


Primary Logo

More from this category

  • Biotechnology, Medical Health Aged Care
  • 24/05/2024
  • 10:53
Neuroscience Research Australia

NeuRA CEO elected as 2024 Fellow of the Australian Academy of Science

Scientia Professor Matthew Kiernan AM CEO at Neuroscience Research Australia has been elected as a 2024 Fellow of the Australian Academy of Science,joining the…

  • Contains:
  • Biotechnology, Science
  • 23/05/2024
  • 07:49
Brandon Capital

Up to $5 million In Funding Available for Dementia and Cognitive Decline Innovations Through CUREator+

23 May 2024 Melbourne: The CUREator+ Dementia and Cognitive Decline incubator program, a partnership between Brandon BioCatalyst, ANDHealth and Dementia Australia, has opened its first funding round. Companies pioneering innovative health technologies to enhance the lives of individuals affected by dementia and cognitive decline are set to receive up to $5 million per project in non-dilutive project funding, a substantial boost for their innovative solutions. Funded by the Federal Government’s $20 billion Medical Research Future Fund (MRFF), the program aims to support the development of novel approaches, spanning therapeutics, diagnostics, assistive and medical devices and digital health technologies, that will…

  • Biotechnology, Seniors Interest
  • 20/05/2024
  • 13:23
Centre for Eye Research Australia, Cerulea Clinical Trials

New centre to bring more international eye clinical trials to Victoria and boost access to sight-saving therapies

A new clinical trial centre launched today in Melbourne will bring more international trials to Victoria and give people living with vision loss and blindness early access to sight-saving therapies.To mark World Clinical Trials Day, Victorian Deputy Premier and Minister for Medical Research, the Hon Ben Carroll, launched Cerulea Clinical Trials - a new specialist ophthalmic clinical trial facility established by the Centre for Eye Research Australia (CERA).Cerulea Clinical Trials is supported by a $10million investment from Breakthrough Victoria and is expected to deliver clinical trials to more than 2500 Victorians a year over the next decade and create 50…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.